Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright

Mural Oncology plc (NASDAQ:MURA) – Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Mural Oncology in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($2.13) per share for the quarter, down from their previous estimate of ($2.05). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period last year, the company posted ($3.57) EPS.

Mural Oncology Stock Up 6.6 %

Shares of MURA opened at $3.90 on Monday. The firm has a 50-day moving average price of $3.87 and a 200 day moving average price of $3.59. The firm has a market capitalization of $67.19 million, a PE ratio of -0.43 and a beta of 3.66. Mural Oncology has a 52-week low of $2.87 and a 52-week high of $5.12.

Hedge Funds Weigh In On Mural Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Commerce Bank bought a new position in Mural Oncology in the 3rd quarter valued at about $39,000. FMR LLC grew its position in Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares in the last quarter. Jane Street Group LLC bought a new position in Mural Oncology in the 4th quarter valued at about $68,000. Two Sigma Advisers LP bought a new position in Mural Oncology in the 4th quarter valued at about $84,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Mural Oncology during the 4th quarter valued at about $94,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.